The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Abstract
OBJECTIVE: Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2 diabetes comorbid with hypertriglyceridemia. RESEARCH DESIGN AND METHODS: Patients were randomly assigned to three groups and received placebo (n = 57), 0.2 mg/day pemafibrate (n = 54), or 0.4 mg/day pemafibrate (n = 55) for 24 weeks (treatment period 1). Subsequently, the patients received follow-up treatment for another 28 weeks (treatment period 2), in which the placebo was switched to 0.2 mg/day pemafibrate. This article presents the results of treatment period 1, which were the primary objectives. RESULTS: The pemafibrate groups showed significantly reduced fasting serum triglyceride levels by ∼45% compared with the placebo group (P < 0.001). Additionally, the pemafibrate groups displayed significant decreases in non-HDL and remnant lipoprotein cholesterol, apolipoprotein (Apo) B100, ApoB48, and ApoCIII levels and significant increases in HDL cholesterol and ApoA-I levels. LDL cholesterol levels were not considerably altered in the pemafibrate groups. Furthermore, the 0.2 mg/day pemafibrate group showed a significantly reduced HOMA–insulin resistance score compared with the placebo group; however, no significant changes compared with placebo were found in fasting plasma glucose, fasting insulin, glycoalbumin, or HbA1c levels. The pemafibrate groups also showed significantly increased fibroblast growth factor 21 levels compared with the placebo group. All groups displayed comparable rates of adverse events and drug reactions. CONCLUSIONS: Pemafibrate significantly ameliorated lipid abnormalities and was well tolerated in patients with type 2 diabetes comorbid with hypertriglyceridemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [13]
In the citing paper
“Phase 2 studies have shown that, as compared with PPARα agonists such as fenofibrate, pemafibrate had greater triglyceride-lowering and HDL cholesterol-raising actions with fewer off-target effects. 9-14”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [13]
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“ined in the FIELD and ACCORD lipid studies (9,40).”
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A., Kosiborod, M., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., Clements, M. A., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 1,026
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
Research works printed but not linked: 2
- Matsuba, 2016, The effects of selective PPAR alpha modulator, K-877, on the insulin sensitivity evaluated by glucose clamp test (Abstract), J-Stage, 59, S462
- Araki, 2014, A highly potent and specific PPAR alpha agonist, K-877, improves lipid profiles and insulin sensitivity in dyslipidaemia subjects; an integrated analysis of 3 phase 2/3 trials (Abstract), Diabetologia, 57, S272
Cited by
Sorted by citations
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
PPAR control of metabolism and cardiovascular functions
Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 981
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Self-citationClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationMetabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Cardiomyopathy in obesity, insulin resistance and diabetes
Nakamura, M., & Sadoshima, J. (2019) · The Journal of Physiology · doi:10.1113/jp276747 · Cited by 294
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 282
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 260
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Self-citationNonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 187
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 150
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationImpact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 116
Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 118
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 114
The Diagnosis and Treatment of Hypertriglyceridemia
Parhofer, K. G., & Laufs, U. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0825 · Cited by 110
Guo, F., Gong, Z., Fernando, T., Zhang, L., Zhu, X., & Shi, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892125 · Cited by 110
Jin, P., Duan, X., Huang, Z., Dong, Y., Zhu, J., Guo, H., Tian, H., Zou, C., & Xie, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02270-3 · Cited by 88
Circulating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 83
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Self-citationThe PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology
Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 79
Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease
Xu, L., Yang, Q., & Zhou, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158465 · Cited by 71
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 71
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 71
Self-citationIda, S., Kaneko, R., & Murata, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0845-x · Cited by 61
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 62
Benefits and risks of the treatment with fibrates––a comprehensive summary
Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 55
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 55
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 55
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 57
Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51
Self-citationLipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 53
Tomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., & Kurihara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235878 · Cited by 49
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Self-citationYamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 49
Self-citationBeyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 49
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46
Self-citationPemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy
Tomita, Y., Lee, D., Miwa, Y., Jiang, X., Ohta, M., Tsubota, K., & Kurihara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176243 · Cited by 46
Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 47
Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 48
Self-citationRole of Vitamin B12 and Folate in Metabolic Syndrome
Ashok, T., Puttam, H., Tarnate, V. C. A., Jhaveri, S., Avanthika, C., Treviño, A. G. T., Sandeep, S. L., & Ahmed, N. (2021) · Cureus · doi:10.7759/cureus.18521 · Cited by 43
Pu, Y., Cheng, C. K., Zhang, H., Luo, J., Wang, L., Tomlinson, B., & Huang, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21970 · Cited by 42
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 43
Self-citationTargeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 42
Zhou, X., Shang, G., Tan, Q., He, Q., Tan, X., Park, K., & Zhao, X. (2021) · Food & Function · doi:10.1039/d1fo01571k · Cited by 40
Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 40
Jiang, J., Wu, C., Zhang, C., Zhang, Q., Yu, L., Zhao, J., Zhang, H., Narbad, A., Chen, W., & Zhai, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031305 · Cited by 37
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 36
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Self-citationThambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 35
Triglycerides and endothelial function: molecular biology to clinical perspective
Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 29
Furukawa, N., Koitabashi, N., Matsui, H., Sunaga, H., Umbarawan, Y., Syamsunarno, M. R. A. A., Yamaguchi, A., Obokata, M., Hanaoka, H., Yokoyama, T., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01711-z · Cited by 29
Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 30
Hatanaka, T., Kakizaki, S., Saito, N., Nakano, Y., Nakano, S., Hazama, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Kashiwabara, K., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6574-20 · Cited by 29
Lee, D., Nakai, A., Miwa, Y., Tomita, Y., Kunimi, H., Chen, J., Ikeda, S., Tsubota, K., Negishi, K., & Kurihara, T. (2022) · The FASEB Journal · doi:10.1096/fj.202200455rrr · Cited by 27
Sex-regulated gene dosage effect of PPARα on synaptic plasticity
Pierrot, N., Ris, L., Stancu, I., Doshina, A., Ribeiro, F., Tyteca, D., Baugé, E., Lalloyer, F., Malong, L., Schakman, O., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800262 · Cited by 27
Hieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 26
Ikeda, S., Sugihara, T., Hoshino, Y., Matsuki, Y., Nagahara, T., Okano, J., Kitao, S., Fujioka, Y., Yamamoto, K., & Isomoto, H. (2020) · Yonago acta medica · doi:10.33160/yam.2020.08.009 · Cited by 25
Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients
Goto, H., Iseri, K., & Hida, N. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad248 · Cited by 24
Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 25
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 23
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 23
Doi, T., Langsted, A., & Nordestgaard, B. G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117556 · Cited by 23
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 25
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21
Xu, Z., Shi, L., Li, D., Wu, Q., Zhang, Y., Gao, M. M., Ji, A., Jiang, Q., Chen, R., Zhang, R., et al. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113173 · Cited by 21
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 18
Chan, H., Ke, L., Lu, H.-T., Weng, S., Chan, H., Law, S., Lin, I., Chang, C., Lu, Y., Chen, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8120542 · Cited by 18
Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Sato, K., Miura, M., Kondo, M., & Endo, H. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63659 · Cited by 18
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
Self-citationSPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 17
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16
Komiya, I., Yamamoto, A., Sunakawa, S., & Wakugami, T. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01434-8 · Cited by 16
Is hypertriglyceridemia atherogenic?
Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14
Self-citationOno, H., Atsukawa, M., Tsubota, A., Arai, T., Suzuki, K. M., Higashi, T., Kitamura, M., Shioda, K., Kawano, T., Yoshida, Y., et al. (2024) · JGH Open · doi:10.1002/jgh3.13057 · Cited by 15
Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14
Self-citationKito, K., Nomoto, H., Sakuma, I., Nakamura, A., Cho, K. Y., Kameda, H., Miya, A., Omori, K., Yanagiya, S., Handa, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110091 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14
Suto, K., Fukuda, D., Shinohara, M., Ganbaatar, B., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.61101 · Cited by 14
Khan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11
Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate
Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11
Iwaki, M., Kobayashi, T., Nogami, A., Ogawa, Y., Imajo, K., Sakai, E., Nakada, Y., Koyama, S., Kurihashi, T., Oza, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088862 · Cited by 10
Management of Mild-to-Moderate Hypertriglyceridemia
Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 9
Downregulated level of insulin in COPD patients during AE; role beyond glucose control?
Ruan, W., Yan, C., Zhu, H., Wang, S., Jia, X., Shao, L., Xu, Z., & Ying, K. (2019) · International Journal of COPD · doi:10.2147/copd.s197164 · Cited by 9
Metabolic Variation Dictates Cardiac Pathogenesis in Patients With Tetralogy of Fallot
Liu, J., Kong, S., Song, S., Dong, H., Zhang, Z., & Fan, T. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.819195 · Cited by 9
Li, W., Xu, J., Guo, X., Xia, X., & Sun, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9762 · Cited by 9
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Seki, M., Nakano, T., Tanaka, S., Matsukuma, Y., Funakoshi, K., Ohkuma, T., & Kitazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02322-4 · Cited by 8
Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64677 · Cited by 8
Self-citation
Metadata
- Authors
- Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., Watada, H., Suganami, H., & Ishibashi, S.
- Affiliations
- Kumamoto University (JP)
- Rinku General Medical Center (JP)
- National Center for Geriatrics and Gerontology (JP)
- Chiba University (JP)
- Tohoku Medical and Pharmaceutical University Wakabayashi Hospital (JP)
- Fukuoka Health Promotion Support Center, Fukuoka, Japan
- Aichi Medical University (JP)
- Shiga University of Medical Science (JP)
- NTT Medical Center Sapporo (JP)
- Yamaguchi University (JP)
- Juntendo University (JP)
- Kowa (Japan) (JP)
- Jichi Medical University (JP)
- Corresponding author
- Araki, Eiichi
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-01-03
- Volume
- 41
- Issue
- 3
- Pages
- 538-546
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2782064714
- Cited by
- 164
- References
- 38
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 17 · 2023: 17 · 2022: 20 · 2021: 25 · 2020: 17 · 2019: 32 · 2018: 13
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K19643, 17H04201, 17H02100, 18K08482, 15H04849)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pemafibrate, PPARα agonist, type 2 diabetes, hypertriglyceridemia, dyslipidemia, triglyceride lowering, remnant cholesterol, apolipoprotein B, apolipoprotein C-III, HDL cholesterol, apolipoprotein A-I, insulin resistance, FGF21, glucose metabolism, drug safety
- MeSH terms
- Aged, Benzoxazoles, Blood Glucose, Butyrates, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Placebos, Hypertriglyceridemia, PPAR alpha, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
